Reviewing Traws Pharma (TRAW) and Its Rivals

Traws Pharma (NASDAQ:TRAW) is one of 1,023 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Traws Pharma to related companies based on the strength of its dividends, risk, valuation, institutional ownership, analyst recommendations, earnings and profitability.

Insider & Institutional Ownership

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.3% of Traws Pharma shares are owned by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Traws Pharma and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Traws Pharma	$230,000.00	-$18.95 million	-0.04
Traws Pharma Competitors	$2.12 billion	$153.56 million	-4.45

Traws Pharma’s competitors have higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Traws Pharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	-60,641.14%	-144.95%	-633.17%
Traws Pharma Competitors	-3,615.94%	-254.37%	-31.21%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Traws Pharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	0	0	0	0	N/A
Traws Pharma Competitors	7300	20167	47073	1104	2.55

As a group, “Pharmaceutical preparations” companies have a potential upside of 58.79%. Given Traws Pharma’s competitors higher possible upside, analysts clearly believe Traws Pharma has less favorable growth aspects than its competitors.

Volatility & Risk

Traws Pharma has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Traws Pharma’s competitors have a beta of 0.81, suggesting that their average share price is 19% less volatile than the S&P 500.

Summary

Traws Pharma competitors beat Traws Pharma on 7 of the 10 factors compared.

Traws Pharma Company Profile

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.